西安诺和达生物科技有限公司
+86 13662665103 Mon–Fri, 09:00–18:00 GMT+8 Contact Us sales@nhdbio.com
Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Quote list

Review quantities before sending your request.

View full quote listContinue browsing productsThis is an enquiry list, not a checkout. No payment is taken.
 Request an Account

Canonical product evidence map

Tirzepatide Evidence Map

A source-linked map of controlled human trials, FDA labeling, mechanism records and material-identity boundaries for tirzepatide.

Browse source recordsOpen product dossier
28
unique source records
5
research types
2022–2026
source-year range

Evidence distribution

See the source mix before reading the conclusions.

A large record count does not imply mature human evidence. The model and source type determine which question a record can answer.

Research type

Research record15
Clinical trial5
Regulatory or database record4
Laboratory study3
Registry or sponsor record1

Study model

Not specified15
Human5
Regulatory / database4
In vitro2
Registry / sponsor1
Analytical / material1

Source-linked records

28 records connected to Tirzepatide

Records are deduplicated by canonical source URL and keep their model, type and evidence-tier labels visible.

Evidence boundary

A source set is not a clinical recommendation.

  • Human, animal, in-vitro, analytical, registry and regulatory records remain separate evidence categories.
  • A published intervention or approved finished medicine does not verify the identity or quality of a catalog research lot.
  • Record inclusion does not mean every finding has been independently replicated or applies outside its stated population and model.

Continue researching

Move between identity, status and analytical meaning.

Product dossierVerified statusAnalytical methodsAdvanced filters

Tirzepatide studies: why can’t you compare the numbers directly?

Even if they all say Tirzepatide, papers may study different populations and different questions. First align the population, comparator, time, and endpoints—then the numbers become comparable.

Weight, blood glucose, and sleep breathing are three different report cards

The original SURMOUNT-1 obesity trial examined weight change in its enrolled population. SURPASS-1 examined blood glucose control in type 2 diabetes. SURMOUNT-OSA studied adults with obesity and obstructive sleep apnea.

In sleep breathing research, AHI records the number of apnea and hypopnea events per hour. It is not a weight percentage, and a reduction in event count cannot be directly rewritten as a weight change with the same number.

Look at the comparator first, then the change

“Decrease from before treatment” and “greater decrease than placebo” are different results. The former includes changes over time and under other conditions; the latter requires comparing two groups and reading the statistical methods clearly.

Even if two papers both report weight change, whether the population has diabetes, the observation time, background measures, and the way dropout data are handled may still differ.

How do you make a truly usable comparison table?

Keep the study name, original link, enrolled population, comparator, primary endpoint, time point, and analysis method in each row. Secondary results can be listed separately, but they cannot be used to override a primary result that was not met.

To compare two materials, prioritize direct comparisons within the same study. Numbers from different trials can help form questions, but they cannot be treated directly as head-to-head conclusions.

Where should product associations go?

After reading a study, then look at the name, form, and specifications of the corresponding research material. Clinical trial formulations, approved drugs, and supplied catalog materials are confirmed separately; a purchasing page does not carry all the clinical conclusions of a paper.

Tirzepatide research reading entry
SURMOUNT-1，2022Population question: Obesity-related populationKey indicator: Weight change
SURPASS-1，2021Population question: Type 2 diabetesKey indicator: Glycemic indicators such as HbA1c
SURMOUNT-OSA，2024Population question: Obesity with sleep apneaKey indicator: Sleep-related indicators such as AHI
Teaching summary. Check the explanation and original sources; this is not a to-scale molecular model or a product test result.
Tirzepatide research reading entry
Original researchPopulation questionKey indicator
SURMOUNT-1，2022Obesity-related populationWeight change
SURPASS-1，2021Type 2 diabetesGlycemic indicators such as HbA1c
SURMOUNT-OSA，2024Obesity with sleep apneaSleep-related indicators such as AHI

Understand one trial before comparing trials

SURMOUNT-1 enrolled 2539 eligible adults with obesity or overweight, excluding diabetes, and followed them for 72 weeks. Mean weight change under the treatment-regimen estimand was −20.9% (95% CI −21.8 to −19.9) in the 15 mg trial group and −3.1% (−4.3 to −1.9) with placebo. Some participants discontinued treatment because of adverse events.

A direct ranking against Retatrutide’s 48-week phase 2 result mixes population, duration and design differences. The two papers can be listed together in an evidence database; that listing is not a head-to-head comparison.

Original sources and further reading

Sources checked on 2026-10-13. Findings apply to the models and materials studied. Batch quality requires records for the actual batch.

Related research materials

TirzepatideView material identity, specifications, and packaging; documentation needs can be raised with an inquiry.

Ask about specifications, quantity, and required materials